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1684-1182/Copyright ª 2015, TaiwanAbstract Background/Purpose: The aim of this study is to determine the best dosing strategy
for vancomycin by studying the associated factors and examining correlations between the area
under the plasma concentration-time curve (AUC) values and trough concentrations in children.
Methods: Children aged 3 months to 18 years were included if they received vancomycin for
more than three doses between January 1, 2010 and December 31, 2012 and had one or more
serum vancomycin trough concentrations. Vancomycin clearance (CL) was calculated using
the following model: CL Z 0.248*Wt0.75*(0.48/serum creatinine)0.361*[ln (age)/7.8]0.995. The
AUC (mg-h/L) was calculated by 24-hour dose (mg/kg/d)/CL(L/h). The value of AUC divided
by the minimum inhibitory concentration (MIC) of vancomycin was AUC/MIC.
Results: A total of 218 children were included. The mean age was 6.0  5.1 years and the mean
body weight was 20  11.7 kg. Vancomycin trough concentrations were moderately correlated
with AUC values (r2Z 0.232, p< 0.01). Dosing of 15mg/kg/dose q6h produced significantly high-
er AUC values (p< 0.001) and vancomycin trough concentrations (p< 0.001) compared to dosing
of 10 mg/kg/dose q6h. In children receiving a 10-mg/kg/dose q6h, 5.6% (5/90) achieved the
target trough concentrations of 15e20 mg/mL and 9.5% (5/90) achieved the goal AUC/
MIC  400. In children receiving a 15-mg/kg/dose q6h, 13% (6/46) achieved the target trough
concentrations of 15e20 mg/mL, whereas 54.3% (25/46) achieved the goal AUC/MIC  400.
Conclusion: A 15-mg/kg/dose q6h compared to a 10-mg/kg/dose q6h is more likely to achieve
target trough concentrations of 15e20 mg/mL and the goal AUC/MIC  400.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
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+ MODELIntroductionVancomycin is a glycopeptide antibiotic that inhibits bac-
terial cell wall synthesis, and is used in the treatment of
infections caused by Gram-positive bacteria such as
Streptococci, Staphylococci, and Enterococcus species.1 It
was first used in 1952 and lost favor due to the introduction
of methicillin in 1958. However, due to the emergence of
methicillin-resistant Staphylococcus aureus (MRSA) world-
wide, the use of vancomycin returned. In Taiwan, MRSA was
first documented in the early 1980s and rapidly increased in
the 1990s.2 A significant trend of a decrease in the inci-
dence of hospital-acquired MRSA was noted in the past 11
years.3 However, community-acquired MRSA infections
have been increasingly reported in pediatric patients since
2000. To date, the rate of methicillin resistance amongst
community-acquired MRSA isolates from pediatric patients
is >50%.4 Vancomycin is still the drug of choice for invasive
MRSA infections.5 As expected, vancomycin will be used
more frequently when treating pediatric patients hospi-
talized for serious staphylococcal infections due to the in-
crease of prevalence. Vancomycin exhibits time-dependent
bactericidal effects when the serum concentration is three
to four times the minimum inhibitory concentration (MIC) of
the organism.6 The increase of antimicrobial resistance in
MRSA urges higher dosing of vancomycin to achieve higher
serum concentrations. In adults, vancomycin area under
the plasma concentration-time curve (AUC) to MIC ratio
(AUC/MIC)  400 best predicts clinical and bacteriological
outcomes for patients with severe infections caused by
MRSA.7 In MRSA bacteremia, a low initial vancomycin AUC/
MIC is an independent risk factor for vancomycin treatment
failure.8 Study has shown that in adults, a vancomycin
trough concentration of 15e20 mg/mL correlates with the
AUC/MIC  400 goal.9 Measuring AUC/MIC by traditional
methods is not practical in a clinical setting because it re-
quires multiple serum vancomycin concentration measure-
ments. Vancomycin trough concentrations have remained
the most commonly used parameter. In 2011, the Infectious
Diseases Society of America released a guideline for the
treatment of MRSA infections. The guideline recommended
vancomycin 15 mg/kg/dose q6h in treating children with
serious or invasive disease and aimed for concentrations of
15e20 mg/mL in children.5 However, studies have shown
that these target trough concentrations of 15e20 mg/mL
are rarely achieved in children and Le et al10 proposed that
AUC/MIC  400 is a more realistic target.
There is as yet no study regarding the target attainment
of vancomycin dosing in Taiwan. Here, we provide the
vancomycin pharmacological data of Taiwanese children,
and determine the target attainment of vancomycin
treatment for invasive MRSA infection by the current dosing
strategy.
Methods
Inclusion criteria
This retrospectively analyzed cohort study was conducted
in a single medical center, the Mackay Memorial Hospital,
Taipei, Taiwan. Children aged 3 months to 18 years werePlease cite this article in press as: Hwang D, et al., Vancomycin do
Immunology and Infection (2015), http://dx.doi.org/10.1016/j.jmii.20included if they received vancomycin for more than three
doses between January 1, 2010 and December 31, 2012,
and had one or more serum vancomycin trough
concentrations.
Data collection
Drug concentrations were routinely monitored in all chil-
dren receiving vancomycin. Dose adjustments were per-
formed based on drug concentrations. Trough
concentrations were obtained 30 minutes before the fourth
vancomycin dose. Creatinine levels were also monitored
routinely. Medical records of children with vancomycin
trough concentrations measured were retrospectively
reviewed. Data including sex, age, weight, serum creati-
nine, vancomycin dosage, and vancomycin trough concen-
trations were collected. MIC data of MRSA isolates in
pediatric participants receiving vancomycin in our hospital
from January 1, 2010 to June 30, 2014 was also collected.
Exclusion criteria
Children aged <3 months were excluded due to the diffi-
culty of creatinine clearance calculation and AUC estima-
tion. Children receiving hemodialysis, peritoneal dialysis,
and continuous venovenous hemofiltration were excluded.
Data analysis
Vancomycin clearance (CL) was calculated using a model
designed by Le et al10: CL Z 0.248*Wt0.75*(0.48/serum
creatinine)0.361*[ln(age)/7.8]0.995. Then, AUC (mg-h/L) was
calculated by 24-hour dose (mg/kg/d)/CL (L/h). The van-
comycin trough concentrations were categorized into
<5 mg/mL, 5e10 mg/mL, 10e15 mg/mL, 15e20 mg/mL, and
>20 mg/mL. The vancomycin AUC was categorized into
<200 mg-hr/L, 201e400 mg-hr/L, 401e600 mg-hr/L, and
600 mg-hr/L. We also calculated the AUC/MIC level ac-
cording to the common vancomycin MIC value to MRSA. The
target attainment of AUC/MIC is 400. The initial dosing of
vancomycin was categorized into seven groups: Group 1:
10 mg/kg/dose q6h, Group 2: 15 mg/kg/dose q6h, Group 3:
15 mg/kg/dose q8h, Group 4: 15 mg/kg/dose q12h, Group
5: 20 mg/kg/dose q6h, Group 6: 10 mg/kg/dose q12h, and
other. The target attainment of different dosing groups was
compared to the recommended vancomycin 15 mg/kg/dose
q6h in treating children.
Statistical analyses
Descriptive analyses were performed to characterize the
demographic and clinical data of children using statistical
software (SPSS, version 15.0; SPSS Science, Chicago, IL,
USA).
Relations of AUC (mg-hr/L), daily dose (mg/kg/d), and
trough concentrations (mg/mL) were analyzed by Pearson’s
correlation test. Student t test or one-way analysis of
variance was used to compare the value of AUC/MIC and
trough concentrations between groups of vancomycin
dosing and daily dose. All tests were two-tailed at the level
of significance of p Z 0.05.sing and target attainment in children, Journal of Microbiology,
15.08.027
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A total of 475 children were screened; 253 children < 3
months old were excluded. Four children aged 3 months to
18 years were excluded due to receiving hemodialysis,
peritoneal dialysis, and continuous venovenous hemofil-
tration. The remaining 218 children were included in the
study. The mean age was 5.97 years and mean body weight
was 20 kg. The categorized dosing of vancomycin, AUC, and
the vancomycin trough concentrations are listed in Table 1.
The correlations between trough concentrations, daily
dose, and AUC are shown in Figure 1. The vancomycin
trough concentration is moderately correlated with daily
dose (mg/kg/d; r2 Z 0.112, p < 0.001), AUC is strongly
correlated with daily dose (mg/kg/d; r2Z 0.619, p < 0.01),
and trough concentration is moderately correlated with
AUC (r2 Z 0.232, p < 0.01).
Among all children, 21.6% (47/218) reached the goal of
AUC/MIC  400, and 7.8% reached the target trough con-
centrations of 15e20 mg/mL. When MIC Z 0.5 mg/mL, 89%
of children achieved AUC/MIC  400. When MICZ 1 mg/mL,
21.6% of children achieved AUC/MIC  400. When
MIC Z 2 mg/mL 1.4% of children achieved AUC/MIC  400
(Figure 2A).
We also did comparisons between groups with distinct
daily doses without consideration of dose interval, which
showed that a higher daily dose has significantly higher AUCTable 1 Demographic data of study group.
Character Mean Standard deviation
Age (y) 6.0 5.7
Body weight (kg) 20.0 17.1
Creatinine level (mg/dL) 0.39 0.28
Dosing (mg/kg/d) 43.7 16.8
No. %
Female sex 111 50.9
Dosage
10 mg q6h 90 41.3
15 mg q6h 46 21.1
15 mg q12h 22 10.1
10 mg q12h 15 6.9
20 mg q6h 7 3.2
15 mg q8h 7 3.2
Other 31 14.2
Trough (mg/mL)
5 48 22.0
6e10 88 40.4
11e15 37 17.0
16e20 17 7.8
>20 15 6.9
AUC (mg-hr/L)
200 22 10.0
200e300 84 38.5
300e400 65 29.8
400e500 20 9.2
500e600 12 5.5
>600 15 6.9
AUC Z area under the plasma concentration-time curve.
Figure 1. Correlations between trough concentrations, daily
dose, and AUC. (A) Correlation of trough concentrations and
daily dose; (B) correlation of AUC and daily dose; and (C)
correlation of trough concentrations and AUC.
Please cite this article in press as: Hwang D, et al., Vancomycin dosing and target attainment in children, Journal of Microbiology,
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+ MODELand vancomycin trough levels (Table 2). The target at-
tainments of different daily doses are shown in Figure 2B.
There were 30 MRSA isolates in pediatric patients
receiving vancomycin in our hospital from January 1, 2010
to June 30, 2014. A total of 22/30 (66.7%) of MRSA isolates
had a vancomycin MIC  0.5 mg/mL, 6/30 (20.0%) had a
vancomycin MIC  1 mg/mL, and 2/30 (6.7%) had a vanco-
mycin MIC Z 2 mg/mL. No vancomycin intermediate
Staphylococcus aureus or vancomycin resistant S. aureus
were found.
When comparisons were made between Group 1 (10 mg/
kg/dose q6h) and Group 2 (15 mg/kg q6h), Group 2 had
significantly higher AUC values (p < 0.001) and vancomycin0
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Figure 2. AUC/MIC target attainment. (A) AUC/MIC target
attainment in all participants; (B) AUC/MIC target attainment
of different daily dose of vancomycin; and (C) AUC/MIC  400
target attainment of different vancomycin dosing group.
AUC Z area under the plasma concentration-time curve;
MIC Z minimum inhibitory concentration.
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90) of children achieved the target trough range of
15e20 mg/mL, whereas 9.5% (5/90) achieved the goal AUC/
MIC  400 when the MIC Z 1 mg/mL, and 90% (81/90)
achieved the goal AUC/MIC  400 when the MIC Z 0.5 mg/
mL; no children achieved the goal AUC/MIC  400 when the
MIC Z 2 mg/mL. In Group 2, only 13% (6/46) of children
achieved the target trough range of 15e20 mg/mL, whereas
54.3% (25/46) achieved the AUC/MIC  400 when
MIC Z 1 mg/mL, and 100% (46/46) achieved the goal AUC/
MIC  400 when MICZ 0.5 mg/mL; no children achieved the
goal AUC/MIC  400 when the MIC Z 2 mg/mL (Figure 2C).Discussion
Due to the high prevalence of MRSA in Taiwan,11,12 vanco-
mycin is usually used as the empirical therapy if patients
are suspected of having serious MRSA infections such as
bacteremia or necrotizing pneumonia, or if other antimi-
crobials like oxacillin or penicillin were not effective. In
larger studies, Eiland et al13 reviewed trough vancomycin
concentrations of 438 participants, when the dosing was
15 mg/kg/dose q6h and showed that only 49% reached
therapeutic trough concentrations (>10 mg/mL). Our study
showed similar results, with only 54.3% (25/46) of children
dosed with 15 mg/kg/dose q6h reaching the trough con-
centrations of >10 mg/mL. Another study, by Frymoyer
et al,14 showed that with a dosing regimen of 15 mg/kg/
dose q6h, only 14% of participants achieved initial trough
concentrations in the range 15e20 mg/mL. Similar to our
study, only 13% (6/46) of participants who received a dosing
regimen of 15 mg/kg/dose q6h achieved vancomycin trough
concentrations of 15e20 mg/mL.
We found that most children do not achieve vancomycin
trough concentrations of 15e20 mg/mL even under high
dosing. Having known the fact that the target trough is not
an optimal target,15 AUC was surveyed as a target for pe-
diatric vancomycin dosing. Our study showed that only 9.5%
of children achieved AUC  400 mg-hr/L by receiving the
10 mg/kg/dose q6h and 54.3% of children achieved
AUC  400 mg-hr/L by receiving the 15 mg/kg/dose q6h.
Similar results were found in a study by Chhim et al,16
which showed that only 17% and 40% of participants ach-
ieved AUC  400 mg-hr/L when receiving 40 mg/kg/d and
60 mg/kg/d, respectively. It is also important to determine
the MIC of the organism being treated. When MICZ 0.5 mg/
mL, > 90% of participants receiving the 10 mg/kg/dose q6h
and the 15 mg/kg/dose q6h achieved AUC/MIC  400. This
suggests that a higher dosing strategy may not be needed
with MICZ 0.5 mg/mL. When MICZ 1 mg/mL, only 54.3% of
participants receiving 15 mg/kg/dose q6h achieved AUC/
MIC  400 and only 13% of participants achieved the target
trough of 15e20 mg/mL. With an MIC Z 2 mg/mL, no case
achieved AUC/MIC  400. Although vancomycin is still the
recommended first line therapy with an MIC of 2 mg/mL,
alternative drugs such as daptomycin, tigecycline, or line-
zolid should be considered.
We found that the predicted AUC correlated with trough
concentrations. Our study showed that trough concentra-
tions of 10e15 mg/mL correlate with AUC Z 400 mg-hr/L.
The study which provided the equation for AUC for oursing and target attainment in children, Journal of Microbiology,
15.08.027
Table 2 The AUC level and trough level by actual daily dose.
Daily dose (mg/kg) Patient no. Mean SD p
AUC (mg-hr/L) <0.001
>60 22 579.5 202.6
50e60 42 436.0 100.9
40e50 42 325.4 90.2
30e40 73 279.9 63.8
30 39 216.9 555.7
Trough level (mg/mL) <0.001
>60 39 14.1 11.1
50e60 25 12.2 7.6
40e50 42 9.2 4.9
30e40 73 7.0 4.3
30 39 7.7 8.0
AUC Z area under the plasma concentration-time curve; SD Z standard deviation.
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mean Cmin of approximately 8e9 mg/mL.
10 One study using
pharmacokinetic modeling by Frymoyer et al17 also showed
a good correlation between AUC and trough concentration.
However, Chhim et al16 found that AUC had a poor corre-
lation with trough concentration. In a previous study, Alford
et al18 also found that glomerular filtration rate equations
do not accurately predict vancomycin trough concentra-
tions in pediatric patients.
Due to the creep of vancomycin MIC of MRSA, the use of an
aggressive dosing strategy for treatment is necessary. In
adults, a review study found that higher trough levels
(>15 mg/mL) were associated with twofold increased odds of
nephrotoxicity relative to lower troughs of <15 mg/mL.19 In
children, whether higher troughs lead to an increase in
vancomycin-induced nephrotoxicity is still in debate. One
recent study showed that maintaining trough concentrations
>15 mg/mL is not associated with an increased rate of
nephrotoxicity in a Paediatric Intensive Care Unit (PICU)
population.20 No documented renal toxicity was noted in our
studyparticipants. Basedonour study, ifweaim forachieving
higher trough concentrations, higher vancomycin doses must
be used andwewill need tomonitor the renal function under
the concern of increasing potential of nephrotoxicity.
The limitations to our study include the small number of
patients sampled and the retrospective nature. In some
patients with complicated underlying conditions such as
prematurity and profound edema, blood sampling is very
difficult. The condition also made it hard to determine the
actual body weight for vancomycin dosing. Rapid changes
of renal function also made the doctor need to adjust the
vancomycin dosing frequently in these patients. Due to the
difficulty in blood sampling, a portion of vancomycin trough
concentrations was not measured in the correct timing.
In conclusion, the predicted AUC correlated with trough
concentrations and vancomycin dosing. Vancomycin dosing
regimens of 15 mg/kg q6h had better achievement of the
target trough concentrations of 15e20 mg/mL and pre-
dicted AUC/MIC  400 in most patients. If the vancomycin
MIC is 0.5 mg/mL, the 15-mg/kg/dose q6h can achieve the
goal of AUC/MIC > 400 in all patients. We suggest the dose
of empiric vancomycin is 15 mg/kg/dose q6h during the
treatment of children with severe MRSA infections.Please cite this article in press as: Hwang D, et al., Vancomycin do
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